

Current Report No 6

Patent filing application for the proprietary set of primers, diagnostic method and the reaction mixture composition to genetically diagnose MRSA (methicillin-resistant staphylococcus aureus) in LAMP technique.

Management Board of Genomtec S.A. (The "Issuer") informs that as of today, i.e. on April 22, 2021, a patent application has been filed for the technology developed by the Issuer. The described application concerns the proprietary set of primers, the diagnostic method and the reaction mixture composition for the genetic diagnosis of MRSA (methicillin-resistant staphylococcus aureus) in the LAMP technique. The application was filed with the Polish Patent Office, Republic of Poland.

Methicillin-resistant staphylococcal strains are a common cause of hospital-acquired infections and pose a significant problem due to the difficulties in their treatment. The microorganism's developed resistance causes no sensitivity to all beta-lactam group of antibiotics - including penicillins, cephalosporins, monobactams and carbapenems. The developed set of primers is a key element of the diagnostic method based on the LAMP technology utilised by the Issuer. Primers initiate the amplification reaction by recognizing a specific fragment of the pathogen's genome. The described patent application prevents the risk of using the same set of primers in an assay by competitors.

The Issuer's Management Board decided that filing the described patent application is a confidential information, as for an entity operating on the molecular diagnostics market it is necessary to effectively protect intellectual property and designs. Properly secured intellectual property and designs may constitute the Issuer's competitive advantage, allowing safer commercialization under condition that full protection is ensured on selected markets.

In the opinion of the Management Board, a high level of intellectual property protection will also provide the Company with a n advantageous negotiating position before signing any commercial contracts with selected partners as part of the commercialization strategy implementation.

Diagnosis of bacterial infections, including MRSA, is one of the key areas of technology developed by the Issuer. For these reasons, in the opinion of the Management Board, this information meets the criteria of confidential information described in Art. 7 sec. 1 MAR.